2024
Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma
Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.Peer-Reviewed Original ResearchRelapsed/refractory multiple myelomaInternational Myeloma Working GroupAdverse eventsGlobal health statusFunctional scalesMultiple symptom scalesPartial responseProteasome inhibitorsMultiple myelomaHealth statusEastern Cooperative Oncology Group performance statusClinical trialsMonoclonal antibody targeting CD38Median progression free survivalRelapsed/refractory multiple myeloma patientsIntroduction of novel therapiesHealth-related quality of lifeClinical response assessmentDaratumumab-based regimensProgression free survivalInfusion-related reactionsLines of therapyPatient-reported quality of life outcomesMean fatigue scoreHealth-related quality
2023
Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use
Belzer A, Nguyen M, Talsania A, Haldas J, Smith J, Leventhal J. Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use. JAMA Dermatology 2023, 159: 109-111. PMID: 36416832, PMCID: PMC9685543, DOI: 10.1001/jamadermatol.2022.4466.Peer-Reviewed Original Research
2021
Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance
Talsania A, Zhang J, Wilson F. Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance. Current Cancer Research 2021, 65-73. DOI: 10.1007/978-3-030-74028-3_4.ChaptersNon-small cell lung carcinomaEGFR-mutant non-small cell lung carcinomaEpidermal growth factor receptorCell lung carcinomaLung carcinomaSmall cell lung carcinomaEGFR-Mutant NonMajor therapeutic challengeCare of patientsPotential therapeutic strategyConstitutive EGFR activationThird-generation EGFR inhibitorsUpregulation of pathwaysGrowth factor receptorResistance mechanismsAdjuvant settingTherapeutic challengeMechanisms of resistanceClinical activityTherapeutic strategiesClinical developmentSmall molecule inhibitorsEGFR inhibitorsFactor receptorEGFR activation
2018
Chapter 7 A Practical Approach to Management of Small Cell Lung Cancer
Talsania A, Chiang A. Chapter 7 A Practical Approach to Management of Small Cell Lung Cancer. 2018, 117-129. DOI: 10.1016/b978-0-323-48565-4.00007-2.Peer-Reviewed Original ResearchSmall cell lung cancerCell lung cancerLung cancerLimited stage small cell lung cancerStage small cell lung cancerSecond-line treatment optionAddition of immunotherapyTime of presentationNCCN guidelinesExtensive diseaseImmunotherapy agentsFrontline treatmentCombination therapyTreatment optionsAggressive formSCLC biologyRB1 lossCancerTherapeutic developmentDiseaseWidespread diseasePossible targetsFunction mutationsContributing factorMolecular determinants